Research programme: molecular glue degraders - Degron Therapeutics/Takeda
Latest Information Update: 06 Jun 2024
At a glance
- Originator Degron Therapeutics
- Class Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Inflammation; Neurological disorders